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Abstract 19 
Asthma is a highly prevalent chronic medical condition affecting an 20 
estimated 12% of pregnant, women each year, with prevalence of asthma 21 
greatest (up to 16%) among the socially disadvantaged. Maternal asthma is 22 
associated with significant perinatal morbidity and mortality including preterm 23 
births, neonatal hospitalisations and low birthweight outcomes each year. We 24 
have identified that the placenta adapts to the presence of chronic, maternal 25 
asthma during pregnancy in a sex specific manner that may confer sex 26 
differences in fetal outcome. The male fetus was at greater risk of a poor 27 
outcome than a female fetus in the presence of maternal asthma and an acute 28 
inflammatory event such as an asthma exacerbation. This review will examine 29 
the role of sex specific differences in placental function on fetal growth and 30 
survival. 31 
  32 
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Introduction 33 
There are known sex specific differences in fetal growth and survival in 34 
pregnancies complicated by asthma which include females being more 35 
susceptible to low birthweight (LBW, <2500g) and small for gestational age 36 
(SGA, <10th birthweight centile), and males more likely to deliver preterm (<37 37 
weeks gestation) and at higher risk of stillbirth especially as asthma worsens 38 
with increasing gestation [1-3]. These sex specific differences may be conferred 39 
by the placenta which adapts to reduce female growth but as a result increases 40 
female survival relative to males in pregnancies complicated by asthma. The 41 
current review assesses sex specific placental adaptations, in the presence of 42 
maternal asthma during pregnancy that may contribute to fetal growth and 43 
survival and considers the consequences of that adaptation for life long health.  44 
Asthma and pregnancy  45 
Asthma is a common co-morbidity to affect women during pregnancy. Its 46 
prevalence is particularly high in Australia affecting 12% of pregnant women  47 
[4] and 3-12% of women worldwide [5]. Asthma has been identified to worsen 48 
as gestation progresses with recurrent uncontrolled asthma [6] and asthma 49 
exacerbations [7] contributing to poor outcomes for the fetus. 50 
The presence of asthma during pregnancy can result in increased maternal 51 
systemic inflammation [8, 9], increased oxidative stress [10, 11], and reduced 52 
levels of maternal oxygen especially when asthma is recurrently uncontrolled or 53 
when women experience an acute exacerbation of asthma [6, 12]. Asthma 54 
exacerbations can result in maternal alkalosis, which can lead to reductions in 55 
the uterine blood flow and fetal oxygenation leading to fetal hypoxia, 56 
hypercapnia, or acidosis under extreme conditions [13]. These maternal factors 57 
may lead to adverse perinatal outcomes with complications of asthma occurring 58 
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early in gestation potentially contributing to preterm delivery and growth 59 
restriction and late gestation exacerbations resulting in stillbirth. 60 
Current research indicates maternal asthma in pregnancy is associated with sex 61 
specific differences  in fetal growth which may be mediated by sex specific 62 
differences in placental function [14]. It has been observed that the female fetus 63 
reduces her growth trajectory in response to maternal asthma by 12% which 64 
confers a survival advantage in the presence of a secondary event such as an 65 
acute exacerbation. The male fetus continues to grow normally in response to 66 
maternal asthma but is at higher risk of a poor outcome following an acute 67 
exacerbation. The placental mechanisms that likely confer these sex specific 68 
fetal differences will be discussed in this review. 69 
Sex differences in placental adaptations to maternal asthma 70 
Global gene expression  71 
Several studies report that there are sex specific global gene differences in the 72 
human placenta [15, 16] which include genes on both the autosomal and sex 73 
chromosomes. Sood et al. [17] reported  increased gene expression related to 74 
immune and inflammatory pathways (JAK1, IL2RB, Clusterin, LTBP, CXCL1, 75 
IL1RL1 and TNF) in female placentae compared to males. Buckberry et al. [18] 76 
reported there were 142 sex-biased human placental genes of which 75 were 77 
expressed higher in female placentae and 67 were expressed higher in male 78 
placentae. Buckberry et al. [18] identified transcription factor genes associated 79 
with mTOR and vascular endothelial growth factor (VEGF) signalling pathways 80 
were sex specifically biased. mTOR signalling is an important nutrient sensor in 81 
the placenta and a regulator of growth and cellular proliferation [19] while 82 
VEGF is a growth factor involved in placental angiogenesis [20]. In particular, 83 
there was a male bias in the numbers of expressed transcription factors 84 
associated with the mTOR pathway which included a number of ribosomal 85 
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proteins (RPS4Y1, RPS4Y2, RPS6KA6) and a protein phosphatase (PPP2R3B).  86 
In female placentae there was a bias towards transcription factors associated 87 
with VEGF signalling which included eukaryotic translation initiation factors 88 
(EIF1AX, EIF2S3). Sex differences in immune gene expression and growth 89 
factor pathways were also identified in placentae of pregnancies complicated by 90 
asthma and suggest it may be these particular biological functions that influence 91 
sex differences in fetal growth and survival.   92 
Placental global gene microarray was conducted on placentae from non-93 
asthmatic and asthmatic pregnancies [15]. The presence of maternal asthma 94 
resulted in 59 gene changes in female placentae, whereas only six gene changes 95 
were identified in male placentae. Using gene network analysis; immune genes, 96 
oxidative stress genes and growth factor genes were significantly altered in 97 
female placentae of pregnancies complicated by asthma (Table 1) [15]. 98 
Alterations in males were primarily associated with acute phase response 99 
signalling and oxidative stress (Table 1). This analysis infers female placentae 100 
of asthmatic pregnancies undergo gene adaptations associated with the 101 
suppression of both immune and growth factor pathways that may contribute to 102 
decreased growth in the presence of maternal asthma and secure a survival 103 
advantage. In contrast, conserved male placental gene expression may promote 104 
continued growth in an adverse maternal environment which results in a 105 
survival disadvantage with further complications.  In both sexes oxidative stress 106 
pathways were comparable suggesting some fundamental mechanisms essential 107 
for survival remain constant.  108 
No sex differences in placental oxidative stress pathways   109 
Asthma itself is associated with increased activation of oxidative stress related 110 
pathways in association with the systemic and chronic presence of inflammation 111 
[10]. Oxidative stress is an imbalance between the cellular generation of 112 
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reactive oxygen species (ROS) and the capacity of anti-oxidants to prevent 113 
oxidative damage, and has been reported to affect placental function in a 114 
number of pregnancy complications [10, 11, 21]. ROS are generated by 115 
enzymatic processes in the mitochondrial membrane where a series of 116 
oxidations, changes in protein conformation and activity often leads to pro-117 
apoptotic events. ROS are sequestered by anti-oxidant enzymes and optimal 118 
function of these anti-oxidants regulates mitochondrial homeostasis. In normal 119 
pregnancies placental anti-oxidant enzymes and associated factors increase as 120 
gestation progresses to compensate for an increase in the generation of ROS. In 121 
placentae from pregnancies complicated by asthma, markers of oxidative stress 122 
were increased [10]. However, anti-oxidant enzyme activity mediated by 123 
superoxide dismutase and thioredoxin reductase also increased in placentae 124 
from pregnancies complicated by asthma as markers of oxidative stress 125 
increased. This compensatory activity by anti-oxidant enzymes did not vary 126 
between the sexes in healthy or asthmatic pregnancies and suggests some 127 
fundamental mechanisms such as the regulation of ROS generation may be 128 
essential for the survival of both sexes. This data along with the microarray data 129 
suggests that the placenta adapts to the presence of maternal asthma by 130 
increasing anti-oxidant activity to counteract the increasing production of ROS 131 
protecting the fetus from maternal asthma-induced oxidative stress. This may 132 
also counteract the effects of asthma-induced inflammation driving the 133 
generation of ROS. 134 
Sex differences in placental immune responses to maternal asthma in 135 
pregnancy and its regulation by cortisol 136 
Placental immune pathways and inflammatory responses were examined in 137 
more detail in pregnancies complicated by asthma. Similar to the global 138 
immune gene bias observed in female placentae of pregnancies complicated by 139 
asthma [22], baseline placental cytokine mRNA expression including TNF-α, 140 
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IL-1β, IL-6, IL-5 and IL-8 was increased compared to female controls [23]. 141 
Female immune gene expression was negatively correlated with cord blood 142 
cortisol concentrations suggesting cortisol may be an important regulator of 143 
immune function in the placenta [23]. Placental cytokine mRNA expression in 144 
males was not affected by the presence of maternal asthma or associated with 145 
cord blood cortisol [23].  146 
In vitro placental explant studies also highlighted there was a sex difference in 147 
immune function between males and females. The timing of the placental 148 
response to an immune challenge in vitro and the regulation of the inflammatory 149 
response by cortisol differed between female and male placentae and in the 150 
presence and absence of maternal asthma [9]. Placentae from asthmatic 151 
pregnancies were more sensitive to an inflammatory stimulus than control 152 
placentae and female placentae from asthmatic pregnancies were more sensitive 153 
to glucocorticoid induced cytokine inhibition, when compared to control female 154 
placentae and male placentae overall [9]. Taken together, these studies suggest 155 
female immune gene pathways and cytokine production in pregnancies 156 
complicated by asthma are more sensitive to the suppressive regulation by 157 
cortisol while male placental immune function appears to be non-responsive to 158 
an inflammatory challenge of asthma or the suppressive effects of cortisol. 159 
Interestingly, many of the immune genes that were identified by microarray to 160 
be altered in female placentae (Table 1) are also regulated by cortisol including 161 
NFκB and CRH. Based on this data we propose that female placentae adapt to 162 
the presence of maternal asthma through suppression of their immune pathways 163 
via increased cortisol exposure. Increased exposure of the female fetus to 164 
cortisol would influence reduced growth via changes in growth factor pathways. 165 
In contrast, a reduced sensitivity to cortisol in males may be a mechanism 166 
allowing continued growth in an asthmatic environment.  167 
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Sex differences in insulin-like growth factor axis (IGF) and its regulation 168 
by cortisol 169 
Growth factor pathways were identified by gene network analysis to change in 170 
placentae of females of pregnancies complicated by asthma [15]. There are 171 
many growth factors produced by the placenta during pregnancy but IGF-1 and 172 
IGF-2 are well characterised polypeptides that have mitogenic properties 173 
including somatic cell growth and proliferation [14]. Studies have found IGF-1 174 
and -2 are required for placental growth and fetal survival. The bioactivity of 175 
IGF-1 and -2 are also dependent on the concentrations of the IGF binding 176 
proteins (IGFBP). The IGFBP-1 isoform has been reported to inhibit IGF-1 177 
binding to IGF-1-cell surface receptors, resulting in decreased IGF-1 mediated 178 
growth and proliferation [24], whereas IGFBP-3 expression has been shown to 179 
be upregulated via testosterone [25, 26] and can potentiate epidermal growth 180 
factor (EGF)-induced cell proliferation and survival [27].  181 
In pregnancies complicated by asthma, males had increased expression of IGF-1 182 
and no change in IGFBP concentrations while females had no changes in any 183 
component of the IGF axis [28]. Both male and female birthweight centiles 184 
were positively correlated with IGF-1 and inversely associated with IGFBP-1. 185 
IGFBP-3 was positively correlated with male birthweight centile indicating this 186 
may be important in male growth relative to females [28]. This was also 187 
supported by the array data indicating IGFBP-3 was downregulated in female 188 
placentae of asthmatic pregnancies [15]. The data suggest male growth is 189 
retained in the presence of maternal asthma through an increase in the 190 
bioactivity of the IGF axis possibly via IGFBP-3 which is regulated by both 191 
cortisol and testosterone.  192 
The female IGF axis in pregnancies complicated by asthma was closely 193 
associated with cortisol concentrations which were not observed in males. In 194 
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particular, female birthweight centile was negatively associated with cortisol 195 
while IGFBP-1 was positively related to cortisol [28]. These data suggest 196 
reduced female growth in pregnancies complicated by asthma is closely linked 197 
to the level of exposure to cortisol which subsequently influences the IGF axis. 198 
These differences in growth factors between the sexes may also be relevant to 199 
mechanisms associated with angiogenesis.  200 
Sex differences in placental angiogenesis and vascular function in 201 
pregnancies complicated by asthma   202 
Angiogenesis, controlled by VEGF and placental growth factor (PlGF) are 203 
important placental mechanisms for the establishment of a low resistance 204 
vascular network in both early and late gestation. The reported female placental 205 
bias in VEGF signalling [18], supported by the microarray data on female 206 
placentae of asthmatic pregnancies where there was no change in VEGF [15], 207 
may be important for retaining placental vascular structure in pregnancies 208 
complicated by asthma and conferring a survival advantage over males.   209 
Stereological studies of placentae of pregnancies complicated by asthma 210 
reported reduced fetal capillary volume relative to non-asthmatic control 211 
subjects especially in moderate and severe asthmatic pregnancies [29]. The 212 
greatest reductions in capillary volume with maternal asthma were observed in 213 
male placentae [29].  In addition to structural alterations in placental vasculature 214 
of pregnancies complicated by asthma, there were functional differences in 215 
vascular responses to dilation and constriction.  216 
Placentae of women with moderate and severe asthma had decreased vascular 217 
dilation and constriction responses relative to healthy placentae.  Placental 218 
vascular responses were further reduced in asthmatic mothers who smoked 219 
cigarettes during pregnancy relative to non-smoking asthmatic women [30]. 220 
Reduced vascular function in relation to both constriction and dilation may be 221 
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indicative of an overall dysfunction in both vascular endothelium and smooth 222 
muscle of the placental circulation.  223 
The hypovascularisation of the villous tree and reduced vascular function in 224 
placentae of asthmatic pregnancies may not be of major concern unless an acute 225 
adverse event such as exacerbation occurs when structurally and functionally 226 
the placenta does not have the capacity to cope with a sudden or extended 227 
reduction in oxygen and nutrient supply, resulting in fetal demise. The higher 228 
incidence of still birth in male fetuses of pregnancies complicated by asthma 229 
often occurred in the third trimester [4, 7]. Late gestation, in particular, is a time 230 
point of high oxygen and nutrient demand where supply to the fetus is 231 
dependent on placental capillary number and optimal vascular function. An 232 
acute adverse event combined with a poorly developed placental vascular 233 
system may be a major contributor to male demise in pregnancies complicated 234 
by asthma. Overall the data collected on placentae from asthmatic pregnancies 235 
suggests that males and females cope differently with a stress. This in part is 236 
driven by a sex specific difference in glucocorticoid biology. 237 
Sex specific differences in placental glucocorticoid bioactivity  238 
Pregnancy induces increased production of endogenous cortisol, with levels 239 
increasing up to four-fold during gestation progression [31]. Several studies 240 
have reported that excessive exposure of the fetus to cortisol early in gestation 241 
restricts growth [32-35]. The placenta institutes several mechanisms (P-242 
glycoprotein, 11β-hydroxysteroid dehydrogenase type2 (11β-HSD2), and 243 
glucocorticoid receptor (GR) isoforms), collectively termed as the placental 244 
glucocorticoid barrier, to protect the fetus from increasing concentrations of 245 
maternal cortisol [36-38]. However, in pregnancies complicated by asthma the 246 
efficacy of the placental glucocorticoid barrier may be impaired.  247 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
In the presence of maternal asthma, placental 11β-HSD2 activity (a catalytic 248 
enzyme that oxidises cortisol to its innate form, cortisone) was decreased 249 
regardless of fetal sex [38, 39]. Reduced 11β-HSD2 activity in male and female 250 
placentae of pregnancies complicated by asthma resulted in the respective 251 
fetuses being exposed to comparably increased cortisol concentrations [40] and 252 
it was speculated for some time that this decrease in 11β-HSD2 function may 253 
contribute to adverse perinatal outcomes associated with growth. However only 254 
females exhibited lower birthweights from pregnancies complicated by asthma 255 
[40]. Males appeared to be unaffected by the anti-proliferative properties of 256 
cortisol inferring the male placentae may have induced a state of glucocorticoid 257 
resistance to facilitate continued fetal growth in a high glucocorticoid 258 
environment.  259 
Current findings suggest the sex specific difference in glucocorticoid sensitivity 260 
may be controlled by differences in the expression of placental GR isoforms. 261 
Female placentae remain sensitive to glucocorticoids in pregnancies 262 
complicated by asthma due to the expression of GRα A, C and D3 isoforms [36, 263 
41], while male placentae expressed the glucocorticoid antagonistic isoform 264 
GR-β and a low trans-activational isoform, GRα D1. Indeed, glucocorticoid 265 
resistance has been well characterised to be mediated through GR-β expression 266 
[42-44], and suggests continued growth of the male fetus may be via the 267 
induction of glucocorticoid resistance. The physiological impact of these GR 268 
isoforms on downstream signalling remain to be clarified but based on the array 269 
data [15] and other studies conducted in this laboratory [9, 23, 28], it is likely 270 
that immune and growth factor pathways are centrally regulated by the 271 
differential expression of GR translation isoforms and splice variants. Although 272 
numerous gene changes in the female placenta of pregnancies complicated by 273 
asthma appear to be driven by cortisol, the factors that regulate continued male 274 
growth are yet to be defined.  275 
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The role of androgens in fetal growth and development 276 
Sex specific placental adaptations that drive continued male growth in a high 277 
glucocorticoid environment may be via the male sex hormones, androgens. 278 
Androgens including testosterone and dihydrotestosterone (DHT) interact with 279 
the androgen receptor (AR) to regulate transcriptional activity of downstream 280 
AR target genes attributed to cellular growth, angiogenesis, and proliferation 281 
[45, 46]. Previous studies have shown that increased cord blood levels of 282 
cortisol were associated with increases in cord blood testosterone. Furthermore 283 
males have increased levels of this androgen derivative compared to females 284 
[47, 48]. Testosterone is synthesised in the adrenal gland, testes, and ovaries, 285 
however studies have reported human syncytiotrophoblast cells are able to 286 
synthesise androgens. Escobar et al. [49] identified syncytiotrophoblast 287 
expresses 17α-hydroxy/17,20-lyase (CYP17), a metabolising enzyme that 288 
converts C21 steroids (such as progesterone) to C19 steroids (such as 289 
testosterone). These placental derived androgens may have physiological effects 290 
including increasing growth in high stress environments such as pregnancies 291 
complicated by asthma. 292 
The human placenta reduces testosterone via 5α-reductase activity which leads 293 
to DHT, a potent metabolite that exhibits higher binding affinity towards the 294 
AR [50]. The human placenta expresses two 5α-reductase isoforms and 295 
previous studies identified that 5α-reductase I expression was increased in male 296 
placentae at term, with no sex specific difference in preterm placentae [51]. 297 
There was no sex specific difference in 5α-reductase II expression in preterm or 298 
term placentae. This data suggests 5α-reductase I may increase testosterone 299 
bioactivity in male placentae and lead to the activation of AR regulated 300 
pathways. 301 
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Interestingly, recent findings in cancer biology suggest glucocorticoids and 302 
androgens may interact to regulate cellular proliferation and growth via an 303 
interaction between AR and GR-β [52, 53]. Inhibition of GR-β in vitro resulted 304 
in decreased growth and proliferation of AR positive cancer cells [54] and these 305 
results suggest that GR-β may affect AR signalling pathways attributed to 306 
cellular growth, however the exact interaction between these steroid receptors 307 
remains undefined. Drawing parallels between cancer and developmental 308 
biology [55] our lab investigated the relationship between AR isoforms and GR-309 
β in male and female placentae from asthmatic and non-asthmatic pregnancies. 310 
It was found that the placenta expresses several different AR isoforms, some of 311 
which may be regulated by GR-β, thereby optimising cellular conditions for 312 
increased or continued male growth (unpublished data), however further studies 313 
focussed on identifying and characterising the exact signalling pathways 314 
involved in AR and GR-β interactions, within the placenta, are needed.  315 
Taken together, the current findings suggests male placentae have higher 316 
bioactive androgen derivatives than females, facilitated by increased 5 α-317 
reductase I expression. The physiological relevance of these findings remain 318 
unclear, however recent work from our lab has identified sex specific changes 319 
in placental AR expression may modify activity of downstream signalling 320 
pathways attributed to growth including IGF axis and angiogenesis via VEGF. 321 
The known in utero mechanisms underlying pathogenic programming of the 322 
fetus include alterations in growth trajectory, organ and tissue development and 323 
changes in homeostasis control systems [56]. This review has provided 324 
evidence to suggest that maternal asthma during pregnancy contributes to 325 
pathogenic programming of the fetus in a sex specific manner [1, 14, 57]. 326 
Specifically, there are reported alterations in growth trajectory in the presence 327 
of maternal asthma, especially in females and adjustments in glucocorticoid 328 
regulated homeostatic control of placental immune and growth pathways for 329 
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both sexes.  Female adjustments in placental function and growth appear to be 330 
essential for survival in utero if the supply of oxygen and nutrients are restricted 331 
following a secondary event. Male placentae and fetuses also adjust homeostatic 332 
cortisol control by inducing a state of glucocorticoid resistance to maintain 333 
normal immune function and growth. This modification in males appears 334 
appropriate for coping with one adverse event but not a secondary event.   335 
Overall it appears a placenta can cope and adequately adapt to one adverse 336 
event in pregnancy but a second hit appears to be the deciding factor on growth, 337 
delivery and survival of the fetusAlthough these adjustments promote survival 338 
in utero they may result in adverse consequences in both early childhood and 339 
later life. 340 
Long term implications of the fetal exposure to asthma in utero 341 
Several reports have shown that uncontrolled asthma during pregnancy was 342 
associated with alterations in childhood neurodevelopment [58], lung function 343 
[59, 60] and an increased risk of endocrine and metabolic disorders based on 344 
Danish epidemiological analyses.  345 
We have observed altered growth trajectories in children whose mothers had 346 
asthma during pregnancy [57]. While children of non–asthmatic mothers did not 347 
deviate from their birth growth trajectory, as projected from their birthweight 348 
centile, 40% of children of asthmatic mothers had already deviated from this 349 
trajectory at 18 months of age, with 78% demonstrating accelerated growth 350 
from birth to 18 months. Interestingly there was a sex difference in the children 351 
that were 2 standard deviations away from the predicted growth trajectory with 352 
60% of females displaying accelerated growth relative to 40% of males. Human 353 
and animal studies have provided evidence that low birthweight followed by 354 
rapid postnatal weight gain are associated with adult cardiovascular disease and 355 
premature mortality [61]. Most of the weight gain is in the form of adipose 356 
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tissue rather than lean tissue with numerous studies reporting deposition 357 
predominantly in the abdomen though usually total body fat is increased overall 358 
[61]. Adults who were IUGR still had a greater abdominal fat content relative to 359 
adults of similar height, weight, age and sex [61]. Increased abdominal fat 360 
predisposes individuals to increased risk of hypertension with aging. The 361 
presence of abdominal fat increases sympathetic nervous system activity 362 
stimulating activation of the kidney renin-angiotensin system and causing 363 
peripheral vasoconstriction and hypertension [62]. It is possible that the 364 
accelerated growth postpartum of children whose mothers had asthma during 365 
pregnancy may predispose them to cardiovascular disease, and endocrine and 366 
metabolic disorders. The long term follow up of these children will be important 367 
to establish the risk of metabolic disease in later life. 368 
 369 
More recent studies suggest there are epigenetic modifications in children 370 
whose mothers had asthma [63]. Blood immune cells from a cohort of 12 month 371 
old children whose mothers were enrolled in the MAP trial [64] had 67 372 
autosomal genes that were differentially methylated relative to children of non-373 
asthmatic mothers. In particular Aurora Kinase A (AURKA) gene was 374 
hypermethylated and correlated with child height and weight [63]. This gene 375 
plays a role in mitosis and is known to be hypermethylated in obese individuals 376 
[65] which may in part contribute to the accelerated growth pattern observed in 377 
children of mothers with asthma [57]. Investigations such as these will be 378 
essential in determining the long term impact of maternal asthma on offspring 379 
health. 380 
 381 
Overall these data indicate that the presence of maternal asthma during 382 
pregnancy results in a placental adaptation that ensures continued growth of the 383 
fetus and survival as long as asthma does not worsen as pregnancy progresses. 384 
Numerous studies have reported that the appropriate management and treatment 385 
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of asthma during pregnancy can prevent growth restriction and prevent the 386 
development of bronchiolitis in early childhood. It is likely that pre-pregnancy 387 
interventions for the management of maternal asthma will be significant in 388 
allowing the placenta and fetus to develop in a manner equivalent to a non-389 
asthmatic pregnancy.  390 
 391 
Conclusion 392 
It is evident from the body of work reviewed that placental alterations to: gene 393 
expression related to the inflammatory and immune pathways; steroid 394 
responsivity; growth factor pathways; and placental vasculature structure and 395 
function can result in sex specific perinatal outcomes associated with growth 396 
and survival from pregnancies complicated by asthma (summarised in Figure 397 
1). Females remain responsive to cortisol throughout pregnancy and it is 398 
postulated the continued sensitivity to cortisol may modulate placental immune 399 
pathways to potentially protect the female fetus from any secondary event that 400 
may include infection. Increased activation of immune pathways can increase 401 
oxidative stress which the placenta again controls via increased anti-oxidant 402 
enzyme activity. However the activation of pro-inflammatory cytokines may 403 
also increase apoptosis to influence reduced female growth. The continued 404 
sensitivity to cortisol was associated with an increase in IGFBP-1 which again 405 
contributes to reduced female growth but may confer a survival advantage.  406 
Although males have increased risk of in utero morbidity and mortality, 407 
glucocorticoid insensitivity, minimal alterations in placental function and 408 
modulated androgen bioactivity may result in unimpaired growth in pregnancies 409 
complicated by asthma however the exact molecular mechanisms underlying 410 
these sex specific growth and survival differences still remain undefined. 411 
Indeed, understanding the complexity of placental adaptations, in the event of 412 
maternal asthma, may provide some insight into: the mechanisms that facilitate 413 
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fetal growth and survival in other inflammatory events of pregnancy such as 414 
pre-eclampsia, infection, autoimmune disease and preterm delivery; as well as 415 
the developmental origins of chronic diseases.  416 
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Table 1: Sex specific placental genes altered by maternal asthma during 604 
pregnancy (adapted from [15, 23, 28]) 605 
 606 
 Female genes 
altered by maternal 
asthma 
Expression 
relative to 
non-
asthmatics 
Male genes 
altered by 
maternal 
asthma  
Expression 
relative to 
non-
asthmatics 
Inflammatory 
genes 
Apoptosis inhibitor 5 
(API5) 
down Coagulation 
Factor 8 
(F8) 
up 
 Complement 
regulatory protein 
(CD59) 
down Heat shock 
protein 70 
1A (Hsp70) 
up 
 Complement Factor 
B (CFB) 
up   
 Chemokine Receptor 
1 (CCR1) 
down   
 Corticotrophin 
releasing hormone 
(CRH) 
up   
 Dystroglycan 1 
(DAG1) 
up   
 Furin (FURIN) up   
 Keratin 1 (KRT1) up   
 Major 
Histocompatability 
complex class II DR 
up   
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beta 1 (HLA_DRB1) 
 Matrix 
metalloproteinase 11 
(MMP-11) 
down   
 Mitogen activated 
protein kinase 10 
(MAPK10) 
down   
 Nuclear Factor 
Kappa B (NFKB) 
down   
 Plasminogen 
activator, urokinase 
receptor (PLAUR) 
down   
 Spermidine/spermine 
N1 aceytransferase 1 
(SAT1)  
down   
 Syndecan 1 (SDC1)  up   
Cytokines TNFα, IL-1β, IL-6, 
IL-8, IL-5 
up   
Growth 
factor genes  
Insulin –like growth 
factor 3 (IGFBP3) 
down No genes  
 Placental Growth 
Factor (PlGF) 
down   
     
Anti-oxidant 
Enzymes 
Glutathione 
Peroxidase (GPX) 
up   
 Malate 
Dehydrogenase 2 
(MDH2) 
down   
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 607 
Figure legend 608 
Figure 1: Summary of key sex specific placental mechanisms that alter fetal survival and growth. 609 
Maternal asthma results in increasing levels of cortisol, testosterone, and oxidative stress, however 610 
the placenta institutes multiple adaptations that can facilitate growth and survival for the developing 611 
fetus. Both female (pink boxes, dashed lines) and male (blue boxes, solid lines) placentae are able to 612 
adequately regulate oxidative stress via increased activity of anti-oxidant enzymes. The female 613 
placenta confers survival for the developing fetus via: modulation of immune function facilitated by 614 
increased expression of glucocorticoid receptor (GR)-αA, C, and D3; and reduced placental blood 615 
flow but retained angiogenesis via vascular endothelial growth factor (VEGF). In contrast, the male 616 
placenta is unable to regulate inflammation due to a state of glucocorticoid receptor (GR)-β induced 617 
glucocorticoid resistance, which results in no change in placental immune function and decreased 618 
angiogenesis, ultimately resulting in decreased survival in the presence of a second hit. Increased 619 
GR-β expression, however, is proposed to increase growth in the developing male fetus via androgen 620 
regulated pathways to elicit increased transcription of IGF-1, increased expression of IGFBP-3 and 621 
transcription factors associated with mTOR signalling. The female placenta, however, limits growth 622 
of the developing fetus via increased expression of insulin like growth factor binding protein (IGFBP)-623 
1 and through cortisol’s anti-proliferative properties.  624 
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